
PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW144900 |
drug action
Haloprogin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:39 Last Updated: October 07, 2023 at 14:39 |
PW176063 |
Haloprogin Predicted Metabolism Pathway newHomo sapiens
Metabolites of Haloprogin are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 13:40 Last Updated: November 29, 2023 at 13:40 |
PW145247 |
drug action
Halothane Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:24 Last Updated: October 07, 2023 at 15:24 |
PW127743 |
drug action
Halothane GABA(A) Anesthetic Action PathwayHomo sapiens
Halothane is a general inhalation anesthetic used for the induction and maintenance of general anesthesia. A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. Halothane causes general anaethesia due to its actions on multiple ion channels, which ultimately depresses nerve conduction, breathing, cardiac contractility. Its immobilizing effects have been attributed to its binding to potassium channels in cholinergic neurons. Halothane's effect are also likely due to binding to NMDA and calcium channels, causing hyperpolarization. It can be found under the brand name Fluothane and the exact mechanism of the action of general anaesthetics has not been delineated. Halothane activates GABAA and glycine receptors. It also acts as an NMDA receptor antagonist, inhibits nACh and voltage-gated sodium channels, and activates 5-HT3 and twin-pore K+ channels. Its action stems from binding to the GABA(A) receptor to depress nerve conduction. Some side effects of using halothane may include cardiorespiratory instability, mild liver dysfunction, and kidney damage.
|
Creator: Hayley Created On: May 30, 2023 at 09:10 Last Updated: May 30, 2023 at 09:10 |
PW128065 |
drug action
Halothane NMDA Antagonist Action PathwayHomo sapiens
Halothone is a general inhalation anesthetic used for the induction and maintenance of general anaesthesia. It provides relatively rapid infuction with little or no excitement. Halothane may not produce sufficient muscle relaxation, so supplemental neuromuscular blocking agents may be required as well.
Halothone is diffused across the blood-brain barrier after being inhaled. It then antagonizes NMDA receptors in the brain. This prevents glutamate from binding to NMDA receptors as readily. This prevents calcium from entering the postsynaptic neuron which leads to hyperpolarization. This hyperpolarization of neurons causes an anaesthetic effect.
|
Creator: Ray Kruger Created On: July 12, 2023 at 15:42 Last Updated: July 12, 2023 at 15:42 |
PW146383 |
drug action
Hard fat Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:04 Last Updated: October 07, 2023 at 18:04 |
PW000218 |
disease
Hartnup DisorderHomo sapiens
Hartunup Disorder (HND, Hartnup Disease) is an autosomal recessive disease caused by a mutation in the SLC6A19 which codes for sodium-dependent neutral amino acid transporter B(0). A deficiency in this enzyme results in accumulation of L-alanine, L-asparagine, L-histidine, indoleacetic acid, L-isoleucine, L-leucine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-valine, and L-tyrosine in urine. Symptoms include pellagra, psychosis, ataxia, and mental retardation. Treatment includes nicotinamide.
|
Creator: WishartLab Created On: August 20, 2013 at 14:52 Last Updated: August 20, 2013 at 14:52 |
PW122027 |
disease
Hartnup DisorderRattus norvegicus
Hartunup Disorder (HND, Hartnup Disease) is an autosomal recessive disease caused by a mutation in the SLC6A19 which codes for sodium-dependent neutral amino acid transporter B(0). A deficiency in this enzyme results in accumulation of L-alanine, L-asparagine, L-histidine, indoleacetic acid, L-isoleucine, L-leucine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-valine, and L-tyrosine in urine. Symptoms include pellagra, psychosis, ataxia, and mental retardation. Treatment includes nicotinamide.
|
Creator: Ana Marcu Created On: September 10, 2018 at 15:51 Last Updated: September 10, 2018 at 15:51 |
PW121802 |
disease
Hartnup DisorderMus musculus
Hartunup Disorder (HND, Hartnup Disease) is an autosomal recessive disease caused by a mutation in the SLC6A19 which codes for sodium-dependent neutral amino acid transporter B(0). A deficiency in this enzyme results in accumulation of L-alanine, L-asparagine, L-histidine, indoleacetic acid, L-isoleucine, L-leucine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-valine, and L-tyrosine in urine. Symptoms include pellagra, psychosis, ataxia, and mental retardation. Treatment includes nicotinamide.
|
Creator: Ana Marcu Created On: September 10, 2018 at 15:49 Last Updated: September 10, 2018 at 15:49 |
PW000181 |
disease
HawkinsinuriaHomo sapiens
Hawkinsinuria (4-Hydroxyphenylpyruvate Hydroxylase Deficiency) is an autosomal dominant disease caused by a mutation in the HPD gene which codes for 4-hydroxyphenylpyruvate dioxygenase. A deficiency in this enzyme results in accumulation of hawkinsin in urine and plasma; cis-4-hydroxycyclohexylacetic acid, trans-4-hydroxycyclohexylaceid, vanillactic acid, 4-hydroxyphenylpyruvic acid, pyroglutamic acid in urine; and L-tyrosine in plasma. Symptoms include ketosis, metabolic acidosis, swimming-pool odor, and mental retardation. Treatment includes a low-protein diet and vitamin C.
|
Creator: WishartLab Created On: August 19, 2013 at 12:05 Last Updated: August 19, 2013 at 12:05 |